The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute ...

CEO Kristian Teär has purchased shares in the period 10 January to 14 January 2025, which as of 13 January 2025 exceeded the reporting limit of EUR 20,000. As of 14 January 2025, Kristian Teär has ...

This is the first randomized controlled trial investigating the efficacy and safety of low-dose prolonged methylprednisolone administration in early ARDS. This study tested a pathophysiologic ...